Tubulis secured a $361 million Series C to accelerate clinical development of its antibody‑drug conjugate (ADC) pipeline and expand manufacturing and translational capabilities. The German biotech, which focuses on next‑generation ADC designs, will use proceeds to advance lead programs toward and through early clinical trials and to scale discovery platforms. Investors signaled renewed appetite for ADC specialists after a period of capital discipline in the sector.